

Artificial Intelligence in Dose Selection and Optimization: A Comprehensive Review on Transforming Modern Drug Development

Authors

Karan Singh¹, Nikita^{*}, Tushar Dhiman², Anshita Dhiman³, Nitesh Kumar⁴, Dr. Kapil Kumar⁵ Verma⁵.

^{1,2,3,4}UG Scholars of Minerva College of Pharmacy Indora, H.P(176401)

⁵ Principal of Minerva college of Pharmacy Indora, H.P.

Corresponding Author

Nikita^{*}, Assistant Professor of Pharmaceutics.

^{*}Department of Pharmaceutics, Minerva College of Pharmacy, Indora H.P(176401)

Abstract

Artificial Intelligence (AI) has been recognized as an important technology in the development of the drug industry. One of the important stages in the development of the drug industry involves the selection and optimization of the appropriate drug dose to ensure the maximum efficacy and the least side effects.

The AI system can process vast amounts of biological, pharmacological, and clinical data to determine the best drug dose. AI technology, with the use of pharmacokinetic and pharmacodynamic data, helps in understanding the absorption, distribution, metabolism, and excretion of the drug, which are important factors in the determination of the appropriate drug dose. In addition, AI helps in the development of personalized medicine, where individualized dose prediction can be made based on characteristics such as age, genetics, body weight, and disease conditions. This helps in improving treatment outcomes and minimizing the risk of adverse drug reactions. AI-based systems can help researchers in designing efficient clinical trials, predicting toxicity, and reducing the time and costs of developing drugs.

Keywords

Artificial Intelligence (AI), Drug Development Dose, Selection Dose, Machine Learning, Clinical Trials Optimization.

1. Introduction

In years we have seen a big increase in large-scale biomedical data. This includes data from genomics, proteomics, electronic health records and clinical trials. All this data has created chances to improve how we optimize drug doses. Traditional statistical methods are often not good enough to handle complex and high-dimensional data. This limitation has made people more interested in using Artificial Intelligence (AI) as a tool to help develop drugs. AI seems powerful for this task. The use of AI, in drug development is becoming more popular. It can handle data and help us make better decisions. For example, AI can help us understand how different people might respond to drug doses. This can lead to personalized and effective treatment plans.[1] Drug development is a long, expensive, and complicated process that usually takes over ten years and requires a large financial investment. One of the most important steps in this process is dose selection and optimization. This step determines how safe and effective a drug is for humans. An incorrect dose can result in treatment failure or serious toxicity. Therefore, optimizing the dose is a key priority in pharmaceutical research.[2] Traditionally, selecting a dose relies on pharmacokinetics (PK) and pharmacodynamics (PD) principles. Pharmacokinetics explains how the body interacts with a drug through absorption, distribution, metabolism, and excretion (ADME). [3]

AI is also changing pharmacokinetic and pharmacodynamic modelling. Traditional PK/PD models often rely on simplifying assumptions and may not fully reflect biological complexity. In contrast, AI-based models learn directly from data and improve prediction accuracy. For example, machine learning algorithms can predict drug concentration-time profiles, identify exposure-response relationships, and simulate different dosing scenarios. These abilities help researchers optimize dose regimens more effectively and lessen the need for extensive experimental studies.[4] Despite its advantages, the implementation of AI in dose selection and optimization faces several challenges. One major issue is the availability and quality of data. Models require large, high-quality datasets for training, but clinical data are often incomplete, heterogeneous, or biased. Additionally, many AI models operate as “black boxes,” making it difficult to interpret their predictions and gain regulatory acceptance. Regulatory agencies such as the FDA and EMA are still developing guidelines for the use of AI in drug development, which may slow its adoption.[5] As researchers use complex computer methods and many data points, artificial intelligence makes predictions more correct. By using those tools, people develop drugs in less time plus for less money. For patients this technology creates medical treatments that match the characteristics of each individual.[6]

2. Role of Artificial Intelligence in Dose Selection and Optimization during Drug Development

The integration of artificial intelligence (AI) into drug development has significantly transformed the process of dose selection and optimization, addressing long-standing challenges associated with variability in pharmacokinetics (PK), pharmacodynamics (PD), and patient heterogeneity. Traditional dose selection approaches rely heavily on empirical methods, such as allometric scaling, non-compartmental analysis, and sequential clinical trial designs, which are often time-consuming, resource-intensive, and limited in their ability to capture complex biological interactions. In contrast, AI-driven methodologies leverage large-scale datasets, advanced computational models, and machine learning (ML) algorithms to enable data-driven, predictive, and adaptive dose optimization strategies. These approaches enhance decision-making by integrating preclinical, clinical, and real-world data to predict optimal dosing regimens with greater accuracy and efficiency.[7] One of the fundamental contributions of AI in dose optimization lies in its ability to model complex PK/PD relationships using nonlinear and high-dimensional data. Machine learning algorithms, including random forests, support vector machines, and neural networks, have demonstrated superior performance in capturing nonlinear dose-response relationships compared to traditional regression-based models.[8] AI algorithms can simulate drug behavior in virtual populations, enabling the evaluation of different dosing scenarios without the need for extensive clinical studies. These simulations can account for special populations, such as paediatric, geriatric, and patients with hepatic or renal impairment, where clinical data may be limited.[9]

3. Fundamentals of Dose Selection in Drug Development

The drug development process has a lot of steps and choosing the right dose is one of them. This is because the dose of a drug will determine how well it works and how safe it is for patients.[10] When we select a dose, we are not just looking for one that has some kind of effect on the body. We want to find the dose that helps patients the most while keeping bad side effects to a minimum.[11] In modern pharmaceutical research, this relationship is commonly described as the dose-exposure-response paradigm, which forms the foundation for rational drug development strategies. A failure to appropriately select the dose may lead either to subtherapeutic outcomes, where the drug fails to produce the desired effect, or to toxicity, which can compromise patient safety and lead to clinical trial failure. Therefore, dose optimization is a central component of regulatory decision-making and clinical success.[12]



Fig. 1: AI for Dose Optimization

3.1. Key Principles of Pharmacokinetics (PK)

Pharmacokinetics is all about how your body deals with a drug. It covers four main things: how the drug gets absorbed, where it spreads throughout your body, how your body breaks it down, and finally, how it gets rid of it. Understanding these steps is really important because it helps us figure out how much of the drug will be in your system at different times and helps us pick the right dose. [13]

Table 1: Key Pharmacokinetic (PK) Parameters in Dose Selection[14]

Parameter	Definition	Role in Dose Selection
C _{max}	Maximum plasma concentration	Indicates peak exposure and potential toxicity
T _{max}	Time to reach C _{max}	Helps determine onset of action
AUC	Area under curve	Measures total drug exposure
t _{1/2} (Half-life)	Time for drug concentration to reduce by half	Determines dosing frequency
Clearance (CL)	Rate of drug elimination	Guides maintenance dose

3.2. Pharmacodynamics (PD) and Dose-Response Relationship

Pharmacodynamics (PD) is the fundamental concept in pharmacology, representing what drugs do to the body biologically and physiologically, as well as detailing the dose-response relationship in terms of the concentration of drug at its site of action to a subsequent therapeutic or toxic response.[15] Whereas pharmacokinetic concepts describe the disposition of a drug through systemic circulation, drug-binding sites, and target tissues, pharmacodynamic concepts describe what happens at that target site. PK and PD are used in tandem to provide a unified perspective that is critical in dose optimization.[16] The lower boundary of the therapeutic window is defined by the minimum effective concentration (MEC), while the upper boundary is determined by the minimum toxic concentration (MTC). Maintaining drug levels within this

range is essential for achieving optimal clinical outcomes.[17]

Table 2: Core Pharmacokinetic Processes and Determinants[18]

PK Process	Key Factors	Clinical Impact
Absorption	Solubility, route, pH	Determines onset of action
Distribution	Blood flow, protein binding	Affects drug targeting
Metabolism	Liver enzymes (CYP450)	Influences drug interactions
Excretion	Renal/hepatic function	Determines drug clearance

3.2.1. Dose-Response Relationship and Mathematical Modeling

The dose-response relationship is one of the most important concepts in pharmacodynamics, describing how the magnitude of drug effect changes with increasing dose or concentration. This relationship is typically represented as a sigmoid (S-shaped) curve, reflecting the gradual increase in response with dose, followed by a plateau at higher concentrations.[19] One of the most widely used models to describe this relationship is the E_{max} model, which defines the maximum achievable effect (E_{max}) and the concentration required to produce half of this effect (EC₅₀). The E_{max} model is particularly useful in drug development because it allows researchers to Advanced PD models also incorporate time-dependent effects, such as delayed drug response, tolerance, and feedback mechanisms, which are particularly relevant in chronic therapies and complex disease conditions. These models improve the accuracy of dose predictions

and enhance the understanding of drug behaviour in real clinical settings. As resultant better outcomes will be achieved by the use of AI methods for mathematical calculations. [20]

3.2.2. Therapeutic Window and Safety Considerations

The concept of the therapeutic window is important in pharmacodynamics, where it is considered the drug concentrations that cause therapeutic effects and no excessive toxicity. Wide therapeutic window drugs tend to be safer to use and easier to dose, while narrow therapeutic window drugs need to be dosed and monitored more closely.[21] The lower boundary of the therapeutic window is defined by the Minimum Effective Concentration (MEC), while the upper boundary is determined by the Minimum Toxic Concentration (MTC). Maintaining drug levels within this range is essential for achieving optimal clinical outcomes.[23] Variability in patient response, due to genetic, physiological, or environmental factors, can significantly affect the therapeutic window.[22]

3.3. Advanced Machine Learning Architectures in Dose Prediction

The evolution of advanced machine learning architectures has significantly enhanced the capability of AI systems to predict optimal dosing regimens. Classical ML algorithms such as random forests and gradient boosting machines are widely used due to their robustness and ability to handle nonlinear relationships; however, recent advancements in deep learning architectures have introduced more sophisticated approaches.[23] Recurrent neural networks (RNN) and Long short-term memory networks (LSTM) are used to model time series PK data in which temporal relationship is inherent within drug concentration profiles. CNN is historically used in image recognition, but it has been developed and used in other structured biological data (e.g. Molecular descriptors, pharmacogenomic data). Transformer models are first developed to model sequences of words but have now been extended to model sequences of molecules and their interactions.[27] This conceptual improvement has great implications for complex diseases such as cancer, autoimmune disease, metabolic syndrome etc where variability of response is marked. AI frameworks hence aid in generation of hypotheses, optimization of dose response curve, support the decisions at any stage of drug development life-cycle.[28]

4. Role of AI in Model-Informed Drug Development (MIDD)

MIDD is an important strategy in the area of optimizing and increasing the rate and success in drug development, and AI has become one of the most essential drivers for developing MIDD approaches. The goal of MIDD is to make decision-making more efficient at each stage of the drug development pipeline. The stages where models are useful at the same time are at drug dosing, clinical trial design, and regulatory assessment stage.[35] AI enhances MIDD by automating complex tasks such as model selection, parameter estimation, and sensitivity analysis.[36] By providing mechanisms to account for a priori knowledge and uncertainty in a predictive model, the Bayesian machine learning paradigm lends itself to adaptable study designs which can adapt dosage schedules in response to intermediate trial data. Large, expensive studies are thereby mitigated, and the time to drug development minimized. [37]

4.1. AI in Precision Medicine and Individualized Dose Selection

Precision medicine represents a novel paradigm that treats individuals based on their own biology. Artificial intelligence plays a significant role in the administration of precision dosing. This process relies on integrating varied datasets (e.g., genomics, proteomics, and metabolomics) with clinical and pharmacological information.[38] Machine learning models can identify biomarkers that predict drug response and toxicity, allowing for the customization of dosing regimens.[39] For instance, AI-based algorithms have been successfully used to determine optimal warfarin dosing by analyzing genetic variants in CYP2C9 and VKORC1 genes. Similarly, in oncology, AI models can predict tumour response to chemotherapeutic agents, enabling dose adjustments that maximize efficacy while minimizing toxicity.[40] The use of wearable devices and continuous monitoring systems further enhances the ability of AI to provide real-time dosing recommendations. This level of personalization not only improves therapeutic outcomes but also reduces the risk of adverse drug reactions, which are a major cause of morbidity and mortality.[24]

5. Applications of Artificial Intelligence in Dose Selection and Optimization

Artificial intelligence has become an essential tool in early-stage drug development, particularly in predicting optimal dosing strategies before human clinical trials begin. During the preclinical phase, large volumes of experimental data are generated from in vitro assays, animal studies, and computational simulations. Traditionally, translating these findings into human dosing regimens has been challenging due to species differences and biological variability. AI overcomes these limitations by integrating multi-source data, including molecular properties, pharmacokinetic parameters, and biological responses, to predict human-relevant dose ranges with improved accuracy.[25]




Fig. 2: Drug Discovery Process

5.1. AI in Early-Stage Drug Development and Preclinical Dose Prediction

Recent interests have also grown around hybrid models which utilize the strengths of mechanistic PK/PD models alongside machine learning techniques. Hybrid models still offer biological understanding but offer superior predictive capability.[26] These models retain biological interpretability while improving predictive accuracy. Such integration facilitates adaptive dose optimization, particularly in therapeutic areas where variability is high, such as oncology and infectious diseases.[27]

Table 3: AI Applications in Preclinical Dose Prediction

Application	AI Method	Outcome
ADME Prediction	Deep Learning	Accurate PK estimation
Species Translation	PBPK + AI	Human dose prediction
Toxicity Prediction	ML Models	Safer dose selection
Molecular Analysis	Neural Networks	Drug optimization

5.2. AI in Clinical Trial Dose Optimization

Artificial intelligence is revolutionizing clinical trial design and execution by enabling adaptive and efficient dose optimization strategies. Traditional clinical trials often follow fixed protocols with predefined dose escalation schemes, which may not adequately account for patient variability. AI-driven approaches allow for real-time analysis of clinical data, enabling dynamic adjustment of dosing regimens based on patient responses.[28] Machine learning models can identify patterns in patient data, such as demographic characteristics, genetic markers, and disease progression, to predict individual responses to treatment.[46] This enables adaptive trial designs where dosing decisions are being refined during the trial in light of interim results, and using Bayesian approaches combined with AI can further improve this through incorporation of a priori information and uncertainty.[29]



Fig. 3: AI-Assisted Clinical Trail Dose Optimization

Clinical implementations of reinforcement learning algorithms have also been used to develop dose-optimization strategies. The algorithms continuously adapt the doses to improve efficacy and limit side effects by learning from patient responses. AI-guided clinical trials have the potential for increased efficiency, reduced study size and increased accuracy of information relating to dose-optimization strategies to further enhance drug approvals. [30]

Table 4: AI in Clinical Dose Optimization[49]

Clinical Phase	AI Role	Benefit
Phase I	Dose escalation	Safety improvement
Phase II	Dose-response modeling	Efficacy optimization
Phase III	Population analysis	Generalization

5.3. AI in Personalized Medicine and Precision Dosing

The application of artificial intelligence in personalized medicine represents one of the most significant advancements in dose optimization. Individual variability in drug response is influenced by genetic, physiological, and environmental factors, making it challenging to determine a universal dosing regimen. AI enables the integration of these diverse data sources to develop personalized dosing strategies tailored to individual patients.[31] Machine learning models can analyze genomic data to identify genetic polymorphisms that affect drug metabolism, such as variations in cytochrome P450 enzymes.[32]




Fig. 4: AI-Guided Personalized Medicine Dosing

These insights allow clinicians to adjust dosing regimens to achieve optimal therapeutic outcomes while minimizing the risk of adverse effects. [33] AI-assisted dosing, especially in oncology, has been quite successful and has contributed to the development of personalized cancer therapies through the ability to tailor treatment with the help of tumor type, and individual patient parameters. Furthermore, in the treatment of chronic diseases, for example diabetes, AI algorithms have shown to allow the adaptation of insulin doses dynamically in real time to optimize the control of the body's glucose levels and prevent possible complications. This ongoing optimization process is essential for ensuring the long-term effectiveness and safety of therapeutic interventions.[34]

5.4. AI in Dose Optimization

The advent of artificial intelligence (AI) has revolutionized the field of pharmaceutical sciences, especially with regard to dose selection and optimization. While traditional methods for dose finding are primarily based on empiric and often trial-and-error approaches that are time consuming and lack comprehensiveness in describing the complex biological system, AI has the power to combine multiple heterogeneous sources of data such as preclinical data, clinical trial data and real-world data to obtain predictive information about the drug response. Utilizing ML techniques, AI algorithms can detect underlying trends within pharmacokinetic and pharmacodynamic datasets thus enabling more rational data-driven optimization. This new paradigm of drug development is critical when the concepts of precision medicine and personalized therapy come into play. Thus, AI can hasten the drug development time and the probability of clinical success by establishing the appropriate dose as early as in the development stages.[35]

6. Advance Approaches and Emerging Trends in AI- Based Dose Optimization

ANNs are especially effective for modeling non-linear relationships such as dose-response, as they can approximate arbitrary functions quite accurately. CNNs build upon this by identifying relevant features in structured data like molecular structures or images and thus improving drug activity and toxicity predictions.[36] RNNs and LSTMs, specifically, are particularly effective for modeling time-dependent pharmacokinetics and pharmacodynamics, as they can identify temporal dependencies and the delay that can occur between drug administration and its effect. This enables the models to predict drug response over time even after multiple administrations, a crucial factor when predicting the impact of dose escalation.[37]

6.1. Deep Learning Models for Complex Dose-Response Relationships

Due to its ability to overcome the shortfalls of classic statistical and mathematical models, Deep learning is one approach to better predict and comprehend dose-response relationship complexities within pharmacology. Conventional pharmacodynamic models, like those derived by Emax or Hill equation, generally utilize simplifying assumptions which

are not always successful at describing nonlinear and dynamics between drug and the organism.[38] On the contrary, deep learning models allow us to infer complex patterns directly from raw data,`

Table 4: Comparison of AI Techniques Used in Dose Optimization[40]

AI Technique	Key Function	Application in Dosing	Advantage	Limitation
Deep Learning (ANN, CNN, RNN)	Pattern recognition	Dose-response prediction	Handles nonlinear data	Needs large datasets
Reinforcement Learning	Decision-making	Adaptive dosing	Real-time optimization	Safety concerns
Machine Learning (Regression, RF)	Prediction	PK/PD modeling	Easy to implement	Less accurate for complex data
Bayesian Models	Probabilistic estimation	Individual dose adjustment	Handles variability	Computationally intensive
Digital Twin Models	Simulation	Virtual dose testing	Personalized therapy	High data requirement

6.2. Reinforcement Learning for Adaptive and Real-Time Dosing

Reinforcement learning can provide a paradigm shift for dose optimization, by allowing the learning system to adapt and make decisions on the fly. Conventional approaches for dosing are fixed regimens, but reinforcement learning systems allow dynamic learning and modification of dose regimens in response to the patient's reaction.[41] In this context, the AI (called agent) interacts with patient environment, by applying doses and then observing responses (therapeutic or side effects). A reward or a punishment is delivered, which allows the AI to take better decision about dosage.[42] Such adaptive learning capabilities can help reinforcement learning models to develop better dosing strategies for dynamically changing clinical environments, where the state of the patient's health status changes over time. For example, in an intensive care setting, patients' drug responses can be significantly different due to organ failures, underlying medical conditions, and co-administered drugs.[43] Reinforcement learning models can adjust dosing in real time to maintain optimal therapeutic levels while minimizing toxicity.[44] Along similar lines in the context of chronic illness, insulin management in diabetes has utilized reinforcement learning to predict trends in blood glucose levels for optimal dosage.[45]

One of the major benefits of reinforcement learning is that treatment plans can be tailored without explicitly coding rules. When applying this to healthcare, safety is of high importance, as erroneous dosing strategies can lead to severe outcomes.[46]

6.3. Integration of Multi-Omics Data for Precision Dose Optimization

Multi-omics data integration-a key factor in AI based precision dose optimization- has allowed us to model individual responses to drugs. The use of multi-omics integrates data on genome, proteome, metabolome and transcriptome in order to describe the complex system. These layers provide varying degrees of regulatory information-gene to protein and metabolite- on what affects the absorption, distribution, metabolism and excretion of a drug.[47] AI approaches are particularly well suited for the analysis of these types of complex and high dimensional data to elucidate correlations and interactions not easily identifiable using classical approaches. An example of a such a complexity relates to genetic polymorphism in the genes responsible for the metabolism of drugs (e.g., cytochrome P450 gene families) as it can have profound effects on drug clearance and bioavailability.[48] AI has been shown to improve prediction models, and this knowledge can then be used to make suggestions about optimal personalized dosing based on these differences. Proteomics and metabolomics may also prove useful to determine state and treatment response.[49] The use of multi-

omics in oncology has led to personalized treatment based on specific tumours.[50] AI models can predict how different tumors will respond to specific drugs, allowing clinicians to select optimal doses that maximize efficacy while minimizing toxicity. This approach is also being applied in other therapeutic areas, including cardiovascular and neurological diseases. While the integration of multi-omics data presents challenges related to data standardization, storage, and analysis, it represents a major step toward truly personalized medicine.[51]

7. Future Scope of AI in Dose Selection and Optimization

Dose optimization is on the brink of a real transformation, thanks to real-time patient monitoring and wearable tech. Think smartwatches, biosensors, and those continuous trackers people wear all busy gathering data like heart rate, blood pressure, glucose levels, and how much someone moves around. Feed all this info into AI systems, and suddenly, it's possible to keep a close eye on what's happening with patients and adjust medication doses on the fly. [52]It's a big shift from fixed schedules to more flexible, personalized routines that actually respond to what's going on in someone's body. Take chronic diseases like diabetes or heart conditions. AI-powered tools can spot changes as they happen and suggest the right dose at the right moment, helping people get better results and dodge side effects. As sensors get sharper and become more common, teaming them up with AI will push personalized medicine even further.[53]

7.1. Expansion of AI Dose Development

Digital twin technology will likely be the lynchpin of future dose optimization strategies. By building a virtual patient twin, simulation can be used to explore how the drug acts in each unique individual, what the patient disease status will be, how the individual will respond to the different dosing options.[54] This enables clinicians to examine, investigate and test various dosing regimens in a risk-free virtual environment before applying it to a patient. As digital twins become more sophisticated with various data streams such as real-time monitoring and multi-omics data, their prediction ability will increase. [55]They will be used most extensively in complex diseases such as cancer, nervous system disorders, and critical care, because patient behaviour in these conditions is unpredictable. Finally, they can also aid in virtual clinical trials which will be faster, less expensive and more ethical.[56]




FIGURE 5: AI Growth in Dose Optimization Over Time

7.2. Application of AI in Special Populations and Rare Diseases

Special populations such as children, the elderly, critically ill patients, and those with rare diseases will receive an increasing share of future AI-assisted dose optimization research. These patients are typically under-represented in clinical trials and there is often sparse data regarding how the dosage in these populations is optimally selected.[57] AI methods can overcome this limitation through real-world data analysis, and can also extrapolate results from comparable patient groups. For instance, models based on machine learning approaches may predict dosages in children on the basis

of appropriate physiological scaling, while adjusting for development, and similarly for elderly individuals as the aging process can affect drug metabolism. For rare diseases the lack of sufficient patient numbers can be supplemented using AI integration of multiple sources in order to facilitate the generation of dose- recommendations.[58]

7.2.1. Challenges in Dose Optimization for Special Populations

Dose optimization in special populations like paediatrics, geriatrics, pregnant women, and critically ill patients is a real challenge due to the heterogeneous physiology and sparse clinical data.[59]

Conventional dosing recommendations are often derived from data in adult population, which may not appropriately account for differences in pharmacokinetic and pharmacodynamic profiles. For example, age-dependent differences in organ function, enzyme activity and body composition of children affect absorption, distribution, metabolism, and elimination of the drugs.[60]

Decreased renal and hepatic function, concomitant administration of many drugs, and altered receptor sensitivity are among a few reasons to exercise extra caution when administering drugs to the elderly patients.[61]

7.2.2. Rare Diseases and Limited Data Challenges

Optimization of dosing regimens is problematic with rare diseases, owing to low patient numbers and thus a lack of clinical trial data. In this situation AI is valuable due to its ability to draw on varied sources of data, case reports, patient registries and real-world evidence. AI can identify analogous diseases and their dose profiles which, by finding common ground with better understood diseases, can inform the prediction of appropriate dose regimens.[62]

8. Regulatory Perspective

The application of Artificial Intelligence (AI) in drug development, particularly in dose selection and optimization, has brought significant regulatory attention due to its impact on patient safety and clinical outcomes.[63] Regulatory frameworks are evolving to address the unique challenges posed by AI-based systems, including issues related to data quality, transparency, and reliability. Agencies such as the U.S. Food and Drug Administration and the European Medicines Agency have initiated guidelines to ensure that AI technologies are developed and implemented responsibly.[64] These guidelines emphasize the importance of using high-quality datasets, ensuring reproducibility of results, and maintaining transparency in model development.[65] A risk-based approach is often adopted, where AI systems are evaluated based on their potential impact on patient safety. Continuous monitoring and updating of AI models are also essential to maintain their accuracy and clinical relevance.[66]

8.1. Guidelines for AI in Drug Development

Guidelines for AI in drug development focus on maintaining scientific rigor and ethical standards throughout the lifecycle of AI systems. Regulatory authorities stress the need for explainable models that allow clinicians and researchers to understand how decisions are made.[67] In addition, adherence to Good Machine Learning Practices (GMLP) and alignment with existing Good Clinical Practice (GCP) standards are strongly recommended. Proper documentation of data sources, model training processes, and validation procedures is required to ensure accountability and facilitate regulatory review.[68] These guidelines aim to create a balance between innovation and safety while promoting the responsible use of AI technologies.[69]

8.2. Validation and Standardization

Validation and standardization are critical components for the successful implementation of AI in dose optimization. AI models must undergo rigorous validation to ensure their accuracy, reliability, and generalizability across different patient populations.[70] This includes internal validation using training datasets, as well as external validation with independent datasets. Clinical validation further confirms the practical utility of AI models in real-world healthcare settings. Standardization involves the use of consistent datasets, validated algorithms, and uniform reporting practices to ensure comparability and reproducibility.[71] Proper documentation and adherence to standardized protocols help build confidence among regulatory authorities and facilitate wider acceptance of AI-based tools.[72]

8.3. Role of Regulatory Agencies

Regulatory agencies play a central role in overseeing the safe integration of AI into drug development processes. Their responsibilities include evaluating and approving AI-based tools, establishing guidelines and policies, and monitoring their performance after implementation. Organizations such as the World Health Organization also contribute by providing global guidance on ethical and responsible AI use. Regulatory bodies work collaboratively with industry and academic institutions to develop adaptive frameworks that can keep pace with rapid technological advancements while ensuring patient safety and data privacy.[73]

9. Future Perspectives

The future of Artificial Intelligence (AI) in dose selection and optimization is very promising. AI is expected to improve how drugs are developed and used in patients. It can make treatments more accurate, faster, and more personalized. This means patients can get better results with fewer side effects. As technology continues to grow, combining AI with new tools and systems will help create better and smarter drug development methods.[75]

9.1 AI and Precision Medicine

AI plays an important role in precision medicine, where treatment is designed for each individual patient. It considers factors like a person's genes, age, and disease condition.[76] By studying large amounts of data, AI can predict how a patient will respond to a drug and help choose the right dose. This approach improves treatment effectiveness and reduces unwanted side effects, leading to better patient care.[77]

9.1. Integration with Wearable Devices

AI can be combined with wearable devices such as smartwatches and fitness trackers to improve patient monitoring.[78] These devices collect important data like heart rate, physical activity, and sleep patterns. AI can use this data to understand how a patient is responding to a drug in real time. Based on this, doctors can adjust the dose when needed. This helps make treatment safer and more effective.[79]

9.2. Digital Twins in Drug Development

Digital twins are virtual models of patients created using computer technology. These models can simulate how a patient's body will respond to a drug. Researchers can test different doses on these virtual models without any risk to real patients. This helps in saving time, reducing costs, and improving accuracy in drug development. Digital twins also help in planning personalized treatments.[80]

9.3. AI-Driven Clinical Decision Support Systems

AI-based Clinical Decision Support Systems (CDSS) help doctors make better decisions about drug dosing. These systems use patient data, medical guidelines, and AI models to give suggestions in real time. They can also warn about possible side effects or drug interactions. This reduces mistakes and improves patient safety. Overall, these systems help in providing better and more efficient healthcare.[81]

10. Conclusion

Artificial Intelligence (AI) is bringing a major change in how drug doses are selected and optimized. It helps researchers and doctors understand complex data better and choose the most effective and safe dose for patients. Compared to traditional methods, AI makes the process faster, more accurate, and more reliable.

AI also supports personalized medicine by considering individual patient differences such as age, genetics, and health condition. This leads to better treatment outcomes and fewer side effects. In addition, AI improves clinical trials, reduces costs, and increases the chances of successful drug development.

Although there are some challenges like data quality, model transparency, and regulatory issues, continuous improvements in technology and proper guidelines can overcome these problems.

In the future, AI will play an even bigger role in healthcare by making treatments more precise, adaptive, and patient-focused. Overall, AI has the potential to make drug development safer, smarter, and more effective for everyone.

References

- [1] Varela-Rey I, Bandín-Vilar E, Toja-Camba FJ, Cañizo-Outeiriño A, Cajade-Pascual F, Ortega-Hortas M, et al. Artificial Intelligence and Machine Learning Applications to Pharmacokinetic Modeling and Dose Prediction of Antibiotics: A Scoping Review. *Antibiotics* 2024;13:1203. <https://doi.org/10.3390/antibiotics13121203>.
- [2] Ros H, Chan N, Cook MT, Shorthouse D. Artificial intelligence and machine learning guided optimization in drug delivery. *Adv Drug Deliv Rev* 2026;232:115781. <https://doi.org/10.1016/j.addr.2026.115781>.
- [3] Joshi S, Sheth S. Artificial Intelligence (AI) in Pharmaceutical Formulation and Dosage Calculations. *Pharmaceutics* 2025;17:1440. <https://doi.org/10.3390/pharmaceutics17111440>.
- [4] Agirbasli M. Influence of Diabetes on CABG Patency. *J Am Coll Cardiol* 2017;70:2604. <https://doi.org/10.1016/j.jacc.2017.07.801>.
- [5] Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. *Nat Med* 2019;25:44–56. <https://doi.org/10.1038/s41591-018-0300-7>.
- [6] M M, S M, Kate SS, Taneja I, Jaiswal S, Pratap B, et al. A review on integrated machine learning and deep learning driven artificial intelligence models for pharmacokinetics and toxicokinetics predictions, and their application. *Drug Metabolism and Disposition* 2026;54:100240. <https://doi.org/10.1016/j.dmd.2026.100240>.
- [7] Sheiner LB, Steimer J-L. Pharmacokinetic/Pharmacodynamic Modeling in Drug Development. *Annu Rev Pharmacol* 2000;40:67–95. <https://doi.org/10.1146/annurev.pharmtox.40.1.67>.
- [8] Tao R, Chan S, Wang J, Wang X, Shi L, Lan X, et al. Pharmacokinetic-pharmacodynamic target attainment analyses as support for meropenem dosing regimens in critically ill adult and elderly patients with *Pseudomonas aeruginosa* infections. *Front Pharmacol* 2025;16. <https://doi.org/10.3389/fphar.2025.1643553>.
- [9] Sheiner LB, Steimer J-L. Pharmacokinetic/Pharmacodynamic Modeling in Drug Development. *Annu Rev Pharmacol Toxicol* 2000;40:67–95. <https://doi.org/10.1146/annurev.pharmtox.40.1.67>.
- [10] Erratum. *Clin Pharmacol Ther* 1981;29:670–670. <https://doi.org/10.1038/clpt.1981.93>.
- [11] Jones R Do, Jones HM, Rowland M, Gibson CR, Yates JWT, Chien JY, et al. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: Comparative assessment of prediction methods of human volume of distribution. *J Pharm Sci* 2011;100:4074–89. <https://doi.org/10.1002/jps.22553>.
- [12] Sheiner LB, Steimer J-L. Pharmacokinetic/Pharmacodynamic Modeling in Drug Development. *Annu Rev Pharmacol Toxicol* 2000;40:67–95. <https://doi.org/10.1146/annurev.pharmtox.40.1.67>.
- [13] Fu C, Chen Q. The future of pharmaceuticals: Artificial intelligence in drug discovery and development. *J Pharm Anal* 2025;15:101248. <https://doi.org/10.1016/j.jppha.2025.101248>.
- [14] Riddick DS, Ding X, Wolf CR, Porter TD, Pandey A V, Zhang Q-Y, et al. NADPH–Cytochrome P450 Oxidoreductase: Roles in Physiology, Pharmacology, and Toxicology. *Drug Metabolism and Disposition* 2013;41:12–23. <https://doi.org/10.1124/dmd.112.048991>.
- [15] Abraham NG, Kappas A. Pharmacological and Clinical Aspects of Heme Oxygenase. *Pharmacol Rev* 2008;60:79–127. <https://doi.org/10.1124/pr.107.07104>.

- [16] Angehrn Z, Haldna L, Zandvliet AS, Gil Berglund E, Zeeuw J, Amzal B, et al. Artificial Intelligence and Machine Learning Applied at the Point of Care. *Front Pharmacol* 2020;11. <https://doi.org/10.3389/fphar.2020.00759>.
- [17] Cerny MA, Spracklin DK, Obach RS. Human Absorption, Distribution, Metabolism, and Excretion Studies: Origins, Innovations, and Importance. *Drug Metabolism and Disposition* 2023;51:647–56. <https://doi.org/10.1124/dmd.122.001006>.
- [18] Fu Y, Taghvafard H, Said MM, Rossman EI, Collins TA, Billiald-Desquand S, et al. A novel cardiovascular systems model to quantify drugs effects on the inter-relationship between contractility and other hemodynamic variables. *CPT Pharmacometrics Syst Pharmacol* 2022;11:640–52. <https://doi.org/10.1002/psp4.12774>.
- [19] Nguyen LM, Li Z, Yan X, Krzyzanski W. A quantitative systems pharmacology model of hyporesponsiveness to erythropoietin in rats. *J Pharmacokinet Pharmacodyn* 2021;48:687–710. <https://doi.org/10.1007/s10928-021-09762-z>.
- [20] Bontempi M. Semi-empirical anticoagulation model (SAM): INR monitoring during Warfarin therapy. *J Pharmacokinet Pharmacodyn* 2022;49:271–82. <https://doi.org/10.1007/s10928-021-09783-8>.
- [21] Maharaj AR, Wu H, Hornik CP, Arrieta A, James L, Bhatt-Mehta V, et al. Use of normalized prediction distribution errors for assessing population physiologically-based pharmacokinetic model adequacy. *J Pharmacokinet Pharmacodyn* 2020;47:199–218. <https://doi.org/10.1007/s10928-020-09684-2>.
- [22] Fu Y, Taghvafard H, Said MM, Rossman EI, Collins TA, Billiald-Desquand S, et al. A novel cardiovascular systems model to quantify drugs effects on the inter-relationship between contractility and other hemodynamic variables. *CPT Pharmacometrics Syst Pharmacol* 2022;11:640–52. <https://doi.org/10.1002/psp4.12774>.
- [23] Maharaj AR, Wu H, Hornik CP, Arrieta A, James L, Bhatt-Mehta V, et al. Use of normalized prediction distribution errors for assessing population physiologically-based pharmacokinetic model adequacy. *J Pharmacokinet Pharmacodyn* 2020;47:199–218. <https://doi.org/10.1007/s10928-020-09684-2>.
- [24] Kazma JM, van den Anker J, Allegaert K, Dallmann A, Ahmadzia HK. Anatomical and physiological alterations of pregnancy. *J Pharmacokinet Pharmacodyn* 2020;47:271–85. <https://doi.org/10.1007/s10928-020-09677-1>.
- [25] Du C, Liu PX, Zheng M. Classification of Imbalanced Electrocardiosignal Data using Convolutional Neural Network. *Comput Methods Programs Biomed* 2022;214:106483. <https://doi.org/10.1016/j.cmpb.2021.106483>.
- [26] Lenders M, Nordbeck P, Kurschat C, Karabul N, Kaufeld J, Hennermann JB, et al. Treatment of Fabry's Disease With Migalastat: Outcome From a Prospective Observational Multicenter Study (FAMOUS). *Clin Pharmacol Ther* 2020;108:326–37. <https://doi.org/10.1002/cpt.1832>.
- [27] Sudduth ER, Trautmann-Rodriguez M, Gill N, Bomb K, Fromen CA. Aerosol pulmonary immune engineering. *Adv Drug Deliv Rev* 2023;199:114831. <https://doi.org/10.1016/j.addr.2023.114831>.
- [28] Du C, Liu PX, Zheng M. Classification of Imbalanced Electrocardiosignal Data using Convolutional Neural Network. *Comput Methods Programs Biomed* 2022;214:106483. <https://doi.org/10.1016/j.cmpb.2021.106483>.
- [29] Li S, Wang Z, Vieira LA, Zheutlin AB, Ru B, Schadt E, et al. Improving preeclampsia risk prediction by modeling pregnancy trajectories from routinely collected electronic medical record data. *NPJ Digit Med* 2022;5:68. <https://doi.org/10.1038/s41746-022-00612-x>.

- [30] Lenders M, Nordbeck P, Kurschat C, Karabul N, Kaufeld J, Hennermann JB, et al. Treatment of Fabry's Disease With Migalastat: Outcome From a Prospective Observational Multicenter Study (FAMOUS). *Clin Pharmacol Ther* 2020;108:326–37. <https://doi.org/10.1002/cpt.1832>.
- [31] Nohara Y, Matsumoto K, Soejima H, Nakashima N. Explanation of machine learning models using shapley additive explanation and application for real data in hospital. *Comput Methods Programs Biomed* 2022;214:106584. <https://doi.org/10.1016/j.cmpb.2021.106584>.
- [32] Joshi S, Sheth S. Artificial Intelligence (AI) in Pharmaceutical Formulation and Dosage Calculations. *Pharmaceutics* 2025;17:1440. <https://doi.org/10.3390/pharmaceutics17111440>.
- [33] Varela-Rey I, Bandín-Vilar E, Toja-Camba FJ, Cañizo-Outeiriño A, Cajade-Pascual F, Ortega-Hortas M, et al. Artificial Intelligence and Machine Learning Applications to Pharmacokinetic Modeling and Dose Prediction of Antibiotics: A Scoping Review. *Antibiotics* 2024;13:1203. <https://doi.org/10.3390/antibiotics13121203>.
- [34] Li B, Tan K, Lao AR, Wang H, Zheng H, Zhang L. A comprehensive review of artificial intelligence for pharmacology research. *Front Genet* 2024;15. <https://doi.org/10.3389/fgene.2024.1450529>.
- [35] Singh S, De A. The paradigm shift in therapeutics: a comprehensive review of artificial intelligence in drug delivery systems. *RSC Pharmaceutics* 2026. <https://doi.org/10.1039/D5PM00235D>.
- [36] Yang J, Zhang D, Cai Y, Yu K, Li M, Liu L, et al. Computational Prediction of Drug Phenotypic Effects Based on Substructure-Phenotype Associations. *IEEE/ACM Trans Comput Biol Bioinform* 2023;20:256–65. <https://doi.org/10.1109/TCBB.2022.3155453>.
- [37] Pak M, Bang D, Sung I, Kim S, Lee S. DGDRP: drug-specific gene selection for drug response prediction via re-ranking through propagating and learning biological network. *Front Genet* 2024;15. <https://doi.org/10.3389/fgene.2024.1441558>.
- [38] Marzouk NH, Selim S, Elattar M, Mabrouk MS, Mysara M. A comprehensive landscape of AI applications in broad-spectrum drug interaction prediction: a systematic review. *J Cheminform* 2025;17:141. <https://doi.org/10.1186/s13321-025-01093-2>.
- [39] Li S, Wang Z, Vieira LA, Zheutlin AB, Ru B, Schadt E, et al. Improving preeclampsia risk prediction by modeling pregnancy trajectories from routinely collected electronic medical record data. *NPJ Digit Med* 2022;5:68. <https://doi.org/10.1038/s41746-022-00612-x>.
- [40] Feltner C, Peat C, Reddy S, Riley S, Berkman N, Middleton JC, et al. Screening for Eating Disorders in Adolescents and Adults. *JAMA* 2022;327:1068. <https://doi.org/10.1001/jama.2022.1807>.
- [41] Liu Y, Jain A, Eng C, Way DH, Lee K, Bui P, et al. A deep learning system for differential diagnosis of skin diseases. *Nat Med* 2020;26:900–8. <https://doi.org/10.1038/s41591-020-0842-3>.
- [42] Lenders M, Nordbeck P, Kurschat C, Karabul N, Kaufeld J, Hennermann JB, et al. Treatment of Fabry's Disease With Migalastat: Outcome From a Prospective Observational Multicenter Study (FAMOUS). *Clin Pharmacol Ther* 2020;108:326–37. <https://doi.org/10.1002/cpt.1832>.
- [43] Foksinska A, Crowder CM, Crouse AB, Henrikson J, Byrd WE, Rosenblatt G, et al. The precision medicine process for treating rare disease using the artificial intelligence tool mediKanren. *Front Artif Intell* 2022;5. <https://doi.org/10.3389/frai.2022.910216>.
- [44] Wang S, Di J, Wang D, Dai X, Hua Y, Gao X, et al. State-of-the-Art Review of Artificial Neural Networks to Predict, Characterize and Optimize Pharmaceutical Formulation. *Pharmaceutics* 2022;14:183. <https://doi.org/10.3390/pharmaceutics14010183>.

- [45] Shen L, Hu M, Xu X, Zhou Y, Wu W, Ge X, et al. Precision dosing of voriconazole in immunocompromised children under 2 years: integrated machine learning and pharmacokinetic modeling. *Front Pharmacol* 2025;16. <https://doi.org/10.3389/fphar.2025.1671652>.
- [46] Mak K-K, Pichika MR. Artificial intelligence in drug development: present status and future prospects. *Drug Discov Today* 2019;24:773–80. <https://doi.org/10.1016/j.drudis.2018.11.014>.
- [47] Mak K-K, Pichika MR. Artificial intelligence in drug development: present status and future prospects. *Drug Discov Today* 2019;24:773–80. <https://doi.org/10.1016/j.drudis.2018.11.014>.
- [48] Lenders M, Nordbeck P, Kurschat C, Karabul N, Kaufeld J, Hennermann JB, et al. Treatment of Fabry's Disease With Migalastat: Outcome From a Prospective Observational Multicenter Study (FAMOUS). *Clin Pharmacol Ther* 2020;108:326–37. <https://doi.org/10.1002/cpt.1832>.
- [49] Komorowski M, Celi LA, Badawi O, Gordon AC, Faisal AA. The Artificial Intelligence Clinician learns optimal treatment strategies for sepsis in intensive care. *Nat Med* 2018;24:1716–20. <https://doi.org/10.1038/s41591-018-0213-5>.
- [50] Mallmann ASV, Chaves R de C, de Oliveira NF, Oliveira ICM, Capibaribe VCC, Valentim JT, et al. Is Riparin III a promising drug in the treatment for depression? *European Journal of Pharmaceutical Sciences* 2021;162:105824. <https://doi.org/10.1016/j.ejps.2021.105824>.
- [51] Klebe G. Broad-scale analysis of thermodynamic signatures in medicinal chemistry: are enthalpy-favored binders the better development option? *Drug Discov Today* 2019;24:943–8. <https://doi.org/10.1016/j.drudis.2019.01.014>.
- [52] John A St., Roth MW, Firlej L, Kuchta B, Charra F, Wexler C. Self-Assembled Two-Dimensional Nanoporous Crystals as Molecular Sieves: Molecular Dynamics Studies of 1,3,5-Tristyrylbenzene-C_n Superstructures. *J Chem Inf Model* 2020;60:2155–68. <https://doi.org/10.1021/acs.jcim.0c00015>.
- [53] Zhang L, Johnson K, Starr J, Milbank J, Kuhn AM, Poss C, et al. Novel Methods for Prioritizing “Close-In” Analogs from Structure–Activity Relationship Matrices. *J Chem Inf Model* 2017;57:1667–76. <https://doi.org/10.1021/acs.jcim.7b00055>.
- [54] Bao J, He X, Zhang JZH. Development of a New Scoring Function for Virtual Screening: APBScore. *J Chem Inf Model* 2020;60:6355–65. <https://doi.org/10.1021/acs.jcim.0c00474>.
- [55] Zhavoronkov A, Ivanenkov YA, Aliper A, Veselov MS, Aladinskiy VA, Aladinskaya A V., et al. Deep learning enables rapid identification of potent DDR1 kinase inhibitors. *Nat Biotechnol* 2019;37:1038–40. <https://doi.org/10.1038/s41587-019-0224-x>.
- [56] Stokes JM, Yang K, Swanson K, Jin W, Cubillos-Ruiz A, Donghia NM, et al. A Deep Learning Approach to Antibiotic Discovery. *Cell* 2020;180:688–702.e13. <https://doi.org/10.1016/j.cell.2020.01.021>.
- [57] Jones IL, Jones SP. Patenting biological simulations in drug discovery. *Drug Discov Today* 2021;26:1557–8. <https://doi.org/10.1016/j.drudis.2021.04.021>.
- [58] Rajkomar A, Oren E, Chen K, Dai AM, Hajaj N, Hardt M, et al. Scalable and accurate deep learning with electronic health records. *NPJ Digit Med* 2018;1:18. <https://doi.org/10.1038/s41746-018-0029-1>.
- [59] Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. *Nat Med* 2019;25:44–56. <https://doi.org/10.1038/s41591-018-0300-7>.
- [60] Kong Y, Yu T. A graph-embedded deep feedforward network for disease outcome classification and feature selection using gene expression data. *Bioinformatics* 2018;34:3727–37. <https://doi.org/10.1093/bioinformatics/bty429>.

- [61] Feng L, Wang Q, Shan C, Yang C, Feng Y, Wu J, et al. An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques. *Nat Commun* 2020;11:4207. <https://doi.org/10.1038/s41467-020-18077-5>.
- [62] Roe K. Dual-peptide ligand masks: a proposed treatment approach to stop prion disease dementias. *Drug Discov Today* 2020;25:15–21. <https://doi.org/10.1016/j.drudis.2019.09.012>.
- [63] Plotegher N, Duchen MR. Mitochondrial Dysfunction and Neurodegeneration in Lysosomal Storage Disorders. *Trends Mol Med* 2017;23:116–34. <https://doi.org/10.1016/j.molmed.2016.12.003>.
- [64] Trobaugh DW, Klimstra WB. MicroRNA Regulation of RNA Virus Replication and Pathogenesis. *Trends Mol Med* 2017;23:80–93. <https://doi.org/10.1016/j.molmed.2016.11.003>.
- [65] Zhang L, Johnson K, Starr J, Milbank J, Kuhn AM, Poss C, et al. Novel Methods for Prioritizing “Close-In” Analogs from Structure–Activity Relationship Matrices. *J Chem Inf Model* 2017;57:1667–76. <https://doi.org/10.1021/acs.jcim.7b00055>.
- [66] Veclani D, Tolazzi M, Cerón-Carrasco JP, Melchior A. Intercalation Ability of Novel Monofunctional Platinum Anticancer Drugs: A Key Step in Their Biological Action. *J Chem Inf Model* 2021;61:4391–9. <https://doi.org/10.1021/acs.jcim.1c00430>.
- [67] Charpentier A, Mignon D, Barbe S, Cortes J, Schiex T, Simonson T, et al. Variable Neighborhood Search with Cost Function Networks To Solve Large Computational Protein Design Problems. *J Chem Inf Model* 2019;59:127–36. <https://doi.org/10.1021/acs.jcim.8b00510>.
- [68] Altae-Tran H, Ramsundar B, Pappu AS, Pande V. Low Data Drug Discovery with One-Shot Learning. *ACS Cent Sci* 2017;3:283–93. <https://doi.org/10.1021/acscentsci.6b00367>.
- [69] Komorowski M, Celi LA, Badawi O, Gordon AC, Faisal AA. The Artificial Intelligence Clinician learns optimal treatment strategies for sepsis in intensive care. *Nat Med* 2018;24:1716–20. <https://doi.org/10.1038/s41591-018-0213-5>.
- [70] Yousefi A, Basu I, Paulk AC, Peled N, Eskandar EN, Dougherty DD, et al. Decoding Hidden Cognitive States From Behavior and Physiology Using a Bayesian Approach. *Neural Comput* 2019;31:1751–88. https://doi.org/10.1162/neco_a_01196.
- [71] Tan JH, Chan CS, Chuah JH. End-to-End Supermask Pruning: Learning to Prune Image Captionin Models. *Pattern Recognit* 2022;122:108366. <https://doi.org/10.1016/j.patcog.2021.108366>.
- [72] Reinhart A. A Review of Self-Exciting Spatio-Temporal Point Processes and Their Applications. *Statistical Science* 2018;33. <https://doi.org/10.1214/17-STS629>.
- [73] Lek M, Karczewski KJ, Minikel E V., Samocha KE, Banks E, Fennell T, et al. Analysis of protein-coding genetic variation in 60,706 humans. *Nature* 2016;536:285–91. <https://doi.org/10.1038/nature19057>.
- [74] Eraslan G, Avsec Ž, Gagneur J, Theis FJ. Deep learning: new computational modelling techniques for genomics. *Nat Rev Genet* 2019;20:389–403. <https://doi.org/10.1038/s41576-019-0122-6>.
- [75] Libbrecht MW, Noble WS. Machine learning applications in genetics and genomics. *Nat Rev Genet* 2015;16:321–32. <https://doi.org/10.1038/nrg3920>.
- [76] Guo Z V., Inagaki HK, Daie K, Druckmann S, Gerfen CR, Svoboda K. Maintenance of persistent activity in a frontal thalamocortical loop. *Nature* 2017;545:181–6. <https://doi.org/10.1038/nature22324>.
- [77] Hoertel N, Blachier M, Blanco C, Olfson M, Massetti M, Rico MS, et al. Author Correction: A stochastic agent-based model of the SARS-CoV-2 epidemic in France. *Nat Med* 2020;26:1801. <https://doi.org/10.1038/s41591-020-1129-4>.

- [78] Nobles AL, Leas EC, Caputi TL, Zhu S-H, Strathdee SA, Ayers JW. Responses to addiction help-seeking from Alexa, Siri, Google Assistant, Cortana, and Bixby intelligent virtual assistants. NPJ Digit Med 2020;3:11. <https://doi.org/10.1038/s41746-019-0215-9>.
- [79] Islam MT, Ross AG, Sleigh AC, Chowdhury F, Khan AI, McMillan NA, et al. A blueprint for eliminating cholera by 2030. Nat Med 2022;28:1747–9. <https://doi.org/10.1038/s41591-022-01898-w>.
- [80] Nemchyna O, Knierim J, Dandel M, Solowjowa N, Schoenrath F, Unbehaun A, et al. Feasibility of two-dimensional speckle-tracking echocardiography of aortic valve in patients with calcific aortic valve disease. J Biomech 2021;122:110474. <https://doi.org/10.1016/j.jbiomech.2021.110474>.
- [81] Virtanen P, Gommers R, Oliphant TE, Haberland M, Reddy T, Cournapeau D, et al. SciPy 1.0: fundamental algorithms for scientific computing in Python. Nat Methods 2020;17:261–72. <https://doi.org/10.1038/s41592-019-0686-2>.